

ADC Therapeutics is advancing what's possible in cancer therapy



ADC Therapeutics

Confronting cancer with the full potential of our science.

ADC Therapeutics is a commercial-stage biotechnology company dedicated to delivering next-generation ADCs for those affected by cancer. We are pioneers in ADC technology and have a deep understanding of the oncology treatment landscape, and we intend to address significant unmet medical needs and improve outcomes for those with difficult-to-treat cancers.

We are confronting cancer with the full potential of our science, bringing unique, targeted therapies and hope to patients and their families.

We strive to be a leading antibody drug conjugate company that transforms the lives of those impacted by cancer.

Our team at ADCT is purpose-driven. We are committed to making a positive impact on patients' lives with our innovative ADC products. We have over a decade of experience in the field of ADCs and we are expanding our technology toolbox to ensure we harness the full potential of ADCs to address the unmet medical needs of patients with cancer.

Ameet Mallik

Chief Executive Officer, ADC Therapeutics



adctherapeutics.com

Loncastuximab tesirine-lpyl receives EMA approval

SEP 2022 Loncastuximab tesirine-lpyl receives positive CHMP opinion in Europe for the treatment of relapsed or refractory diffuse large B-cell lymphoma

AUG 2022 ADCT announces exclusive licensing agreement with Sobi to develop and commercialize loncastuximab tesirine-lpyl in Europe and select international territories

JAN 2022 ADCT announces exclusive licensing agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) for the development and commercialization of loncastuximab tesirine-lpyl for all hematologic and solid tumor indications in Japan

BLA acceptance with priority review for loncastuximab tesirine-lpyl

BLA submission for loncastuximab tesirine-lpyl

CD-19 targeted, lead investigational compound loncastuximab tesirine-lpyl receives FDA approval

NOV 2020 FDA accepts BLA and grants priority review for loncastuximab tesirine-lpyl for CD-19 directed therapy

DEC 2020 ADC Therapeutics and Overland Pharmaceuticals form Overland ADCT BioPharma to develop and commercialize ADCT products, including loncastuximab tesirine-lpyl, in greater China and Singapore

ADC Therapeutics joins the NYSE as ticker ADCT

OCT 2019 1st patient enrolled in Phase 2 clinical trial of CD-25 targeted investigational compound in relapsed or

refractory Hodgkin lymphoma

1st patient dosed in pivotal Phase 2 trial with loncastuximab tesirine-lpyl

Our History

MAR 2016 1st patient enrolled in Phase 1 clinical trial of lead investigational compound targeting CD-19 (loncastuximab tesirine-lpyl) in positive B-Cell non-Hodgkin lymphoma

ADC Therapeutics founded as a spinoff from Spirogen Ltd, an early innovator in PBD-based ADC research

antibody drug conjugate (ADC) biologics license application (BLA) pyrrolobenzodiazepine (PBD)








One of the ways we are delivering on the promise of science -

advancing next-generation PBD-based ADCs.

Our proprietary PBD-based ADCs are expected to provide a novel way to treat hematological cancers and solid tumors, address significant unmet medical needs, and improve the lives of patients with cancer.



ADVANCING



at's possible



Scan the QR code to view the ADC Therapeutics pipeline or visit adctherapeutics.com

For general inquiries, please contact info@adctherapeutics.com

For more information about our clinical trials and research, please contact medicalinformation@ADCTherapeutics.com. or call 1.855.690.0340





Stay informed